Researcher
Tim Lammens
- Keywords:acute myeloid leukemi, inherited predisposition for cancer, asparaginase, neuroblastoma, juvenile myelomonocytic leukemia, pediatric oncology
- Disciplines:Molecular and cell biology not elsewhere classified, Oncology not elsewhere classified, Genomics, Paediatrics
Affiliations
- Department of Internal Medicine and Pediatrics (Department)
Member
From1 Oct 2018 → Today - Department of Pediatrics and medical genetics (Department)
Member
From1 Jun 2009 → 30 Sep 2018 - Department of Plant Biotechnology and Bioinformatics (Department)
Member
From1 Oct 2004 → 31 Jan 2009
Projects
1 - 10 of 16
- Evaluating the predictive power of a set of adrenergic and mesenchymal coding - and - noncoding RNAs in neuroblastoma.From1 Mar 2024 → TodayFunding: Foreign foundations, funds with scientific view
- Facility : Patiënt-afgeleide xenograft modellen – UGent;From1 Feb 2024 → TodayFunding: BOF - research organisations
- Establishing safety and efficacy of an improved Asparaginase in dog models: final preparation for Phase I clinical trialFrom1 Jan 2024 → TodayFunding: Nonprofit institution or equivalents
- A SIOPEN pragmatic clinical trial to MOnitor NeuroblastomA relapse with LIquid biopsy Sensitive AnalysisFrom1 Jan 2024 → TodayFunding: HORIZON.2.1 - Health
- Towards clinical testing of novel stabilized less toxic asparaginases for the treatment of acute lymphoblastic leukemiaFrom20 Dec 2023 → TodayFunding: IOF - technology validation in lab
- Research assignment of Prof. dr. Tim Lammens, framing the ongoing clinical-translational research at the Department of Pediatric Hematology-Oncology and Stem Cell TransplantationFrom1 Oct 2023 → TodayFunding: Nonprofit institution or equivalents
- Preclinical validation of a less toxic variant for paediatric leukemiaFrom1 Oct 2022 → 30 Sep 2023Funding: Nonprofit institution or equivalents
- A patient derived xenograft (PDX) platform for in vivo evaluation of novel anticancer therapiesFrom1 May 2022 → TodayFunding: FWO Medium Size Research Infrastructure
- The impact of magnetic particulate matter (mPM) pollution as a contributing factor for development of childhood cancer: an in vitro and in vivo molecular and cellular analysis.From1 Nov 2021 → 31 Oct 2022Funding: Nonprofit institution or equivalents
- The use of a less toxic alternative asparaginase variant to treat metastatic breast cancerFrom1 Oct 2021 → TodayFunding: BOF - projects
Publications
21 - 30 of 36
- Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma(2018)
Authors: Renate De Smedt, Sofie Peirs, Julie Morscio, Filip Matthijssens, Juliette Roels, Lindy Reunes, Béatrice Lintermans, Steven Goossens, Tim Lammens, Nadine Van Roy, et al.
Pages: e17 - e20 - Genes at the crossroad of primary immunodeficiencies and cancer(2018)
Authors: Charlotte Derpoorter, Victoria Bordon Maria, Genevieve Laureys, Filomeen Haerynck, Tim Lammens
- Retrospective study of infant leukaemia in the University Hospitals of Leuven and Ghent(2018)
Authors: Barbara De Moerloose, E Nauwynck, K Arts, Leen Willems, V Labarque, Tim Lammens, A Uyttebroeck
Pages: 57 - 63 - Recurrently affected genes in juvenile myelomonocytic leukaemia(2018)
Authors: Julia C Obenauer, Francois G Kavelaars, Mathijs A Sanders, Andrica CH de Vries, Valerie de Haas, H Berna Beverloo, Barbara De Moerloose, Tim Lammens, Michael Dworzak, Remco M Hoogenboezem, et al.
Pages: 135 - 138 - Event-free survival of infants and toddlers enrolled in the HR-NBL-1/SIOPEN trial is associated with the level of neuroblastoma mRNAs at diagnosis(2018)
Authors: Maria V Corrias, Stefano Parodi, Andrei Tchirkov, Tim Lammens, Ales Vicha, Claudia Pasqualini, Catarina Träger, Yania Yáñez, Sandro Dallorso, Luigi Varesio, et al.
- Current understanding and future research priorities in malignancy associated with inborn errors of immunity and DNA repair disorders : the perspective of an interdisciplinary working group(2018)
Authors: Simon Bomken, Jutte van der Werff Ten Bosch, Andishe Attarbaschi, Chris M. Bacon, Arndt Borkhardt, Kaan Boztug, Ute Fischer, Fabian Hauck, Roland P. Kuiper, Tim Lammens, et al.
- The genetic basis and cell of origin of mixed phenotype acute leukaemia(2018)
Authors: Thomas B. Alexander, Zhaohui Gu, Ilaria Iacobucci, Kirsten Dickerson, John K. Choi, Beisi Xu, Debbie Payne-Turner, Hiroki Yoshihara, Mignon L. Loh, John Horan, et al.
Pages: 373 - 379 - Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients(2018)
Authors: Fjoralba Zeka, Anneleen Decock, Alan Van Goethem, Katrien Vanderheyden, Fleur Demuynck, Tim Lammens, Hetty Helsmoortel, Joëlle Vermeulen, Rosa Noguera, Ana P. Berbegall, et al.
- Genetic characterization and therapeutic targeting of MYC translocated pediatric T-cell acute lymphoblastic leukemia(2016)Volume: 76
Authors: Gloria Milani, Kaat Durinck, Filip Matthijssens, Sofie Peirs, Tim Pieters, Lindy Reunes, Béatrice Lintermans, Niels Vandamme, Tim Lammens, Yunlei Li, et al.
Number of pages: 1 - Genomic landscape of pediatric mixed phenotype acute leukemia(2016)Volume: 128
Authors: Thomas B Alexander, Zhaohui Gu, John K Choi, Mignon Loh, John Horan, Barbara Buldini, Giuseppe Basso, Sarah Elitzur, Valerie de Haas, C Michel Zwaan, et al.
Number of pages: 1